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Background. Human cytomegalovirus (hCMV) is involved in the pathogenesis of atherosclerosis. We have previously shown in
patients with atherosclerosis that antibodies directed against the hCMV-derived proteins US28 and UL122 are able to induce
endothelial cell damage and apoptosis of non-stressed endothelial cells through cross-rection with normally expressed surface
molecules. Our aim was to dissect the molecular basis of such interaction and to investigate mechanisms linking innate
immunity to atherosclerosis. Methodology/Principal Findings. We analysed the gene expression profiles in endothelial cells
stimulated with antibodies affinity-purified against either the UL122 or the US28 peptides using the microarray technology.
Microarray results were validated by quantitative PCR and by detection of proteins in the medium. Supernatant of endothelial
cells incubated with antibodies was analysed also for the presence of Heat Shock Protein (HSP)60 and was used to assess
stimulation of Toll-Like Receptor-4 (TLR4). Antibodies against UL122 and US28 induced the expression of genes encoding for
adhesion molecules, chemokines, growth factors and molecules involved in the apoptotis process together with other genes
known to be involved in the initiation and progression of the atherosclerotic process. HSP60 was released in the medium of
cells incubated with anti-US28 antibodies and was able to engage TLR4. Conclusions/Significance. Antibodies directed
against hCMV modulate the expression of genes coding for molecules involved in activation and apoptosis of endothelial cells,
processes known to play a pivotal role in the pathogenesis of atherosclerosis. Moreover, endothelial cells exposed to such
antibodies express HSP60 on the cell surface and release HSP60 in the medium able to activate TLR4. These data confirm that
antibodies directed against hCMV-derived proteins US28 and UL122 purified from patients with coronary artery disease induce
endothelial cell damage and support the hypothesis that hCMV infection may play a crucial role in mediating the
atherosclerotic process.
Citation: Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, et al (2007) Endothelial Cells’ Activation and Apoptosis Induced by a Subset of
Antibodies against Human Cytomegalovirus: Relevance to the Pathogenesis of Atherosclerosis. PLoS ONE 2(5): e473. doi:10.1371/journal.
pone.0000473
INTRODUCTION
Atherosclerosis is the primary cause of morbidity and mortality
worldwide. It is a multifactorial disorder influenced by genetic [1]
and environmental factors [2]. Indeed the genetic background is
greatly influenced by classical environmental risk factors, such as
cholesterol, diabetes, hypertension, obesity and smoking. In
addition inflammation, infection and autoimmunity have been
recently suggested to play a role in the pathogenesis of the disease
[3]. Infectious agents seem to be involved in endothelium damage
by inducing an autoimmune response to Heat Shock Proteins
(HSPs) [4]. Antibodies against HSP60 are present in the majority
of patients with coronary artery disease and their titre correlates
with disease severity [5].
We have previously shown that autoantibodies against HSP60
are present in most atherosclerotic patients and that these
autoantibodies are directed to an aminoacid sequence at position
153-163 of HSP60 that shows homology with two human
cytomegalovirus (hCMV)-derived proteins, UL122 and US28
[ref. 6]. Anti-HCMV antibodies were present in a slightly higher
percentage in CAD patients than in controls, however only the
sera of patients with CAD showed antibodies against the identified
viral peptides. Both viral peptides, UL122 and US28, show
sequence similarity with molecules normally expressed on
endothelial cell surface: US28 shows homology with integrin
alpha 6 (CD49f) and UL122 with connexin 45 and CD151 [ref. 6].
IgG antibodies affinity purified against the HSP60 peptide from
the sera of ten patients with coronary artery disease (CAD) bound
endothelial cell derived HSP60, recombinant human HSP60 and
recognized the hCMV-derived proteins UL122 and US28 [6].
Antibodies against the HSP60 peptide affinity purified from the
serum samples of controls did not cross-react with the viral
proteins. The IgG antibody component affinity purified against
the viral peptides from the patients with CAD, recognized both the
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CAD did not show antibodies against the viral peptides [6].
Antibodies directed against HSP60 and viral peptides bound
endothelial cells upon interaction with the cell surface receptors
sharing sequence homology with the viral peptides, through
a mechanism of molecular mimicry, and induced apoptosis of non-
stressed endothelial cells [6], considered a primary event in the
pathogenesis of atherosclerosis [7,8]. Moreover, HSP60 exposed
on the surface of stressed endothelial cells could amplify the
antibody aggression through cross-recognition of the anti-viral
antibodies [6].
Taking advantage of the results previously obtained, we aimed
at analyzing the molecular effects of the identified anti-hCMV
antibodies on endothelial cells, using the DNA microarray
approach, in order to ascertain whether the sets of genes
modulated by anti-hCMV-derived proteins UL122 and US28
antibodies, are associated with the pathogenesis of atherosclerosis.
We found indeed that most of the genes modulated are known to
be associated with the atherosclerotic process. Moreover such
antibodies induced release of HSP60 able to activate Toll-Like
Receptor 4 (TLR4).
MATERIAL AND METHODS
Patients
The clinical characteristics of the ten patients with angiographic
evidence of coronary artery disease, whose sera were used to
obtain affinity purified antibodies against the peptides, have
already been described elsewhere [6].
Purification of anti-US28 and anti-UL122 IgG
antibodies
The UL122-derived peptide (GPKKKSKRIS), the US28-derived
peptide (TDVLNQSKPVT) and the irrelevant control peptide
(VTLPKDSDVELP) chosen on the basis of its absence of relevant
homology with the viral peptides and with the endothelial
molecules connexin 45, CD49f and CD151, were synthesized by
solid phase synthesis with the 9-fluorenylmethoxycarbonyl strategy
[6].
To affinity purify IgG antibodies against either the UL122 or
the US28 peptide or the control peptide, each peptide (5 mg/g of
dried sepharose powder) was coupled to sepharose 4B (Pharmacia
Uppsala, Sweden), according to the manufacturer’s instructions.
Pooled sera from the 10 different patients analysed were diluted in
PBS and bound immunoglobulins were eluted with 0,1 M glycine
pH 2,5 and dialysed against PBS [6].
Cell culture and apoptosis
Human endothelial cells (HUVECs) and their growth media were
purchased from Promocell Bioscience Alive (Heidelberg, Ger-
many). HUVECs were used between passages 2 and 5. Cell
monolayers were stimulated with antibodies purified against the
UL122 or US28 peptide or the irrelevant control peptide (20
microgram/ml) and apoptosis evaluated at various intervals of
time. Tumor necrosis factor alpha (TNFalpha 50 mg/L) was used
as positive control to induce endothelial cell apoptosis. The extent
of DNA fragmentation was quantified using a commercially
available kit (Roche Biochemical, Basel, Switzerland). The
enrichment of mono-and oligo-nucleosomes released into the
cytoplasm is calculated as absorbance of sample cells (cells treated
with antibodies)/absorbance of control cells (cells not exposed to
antibodies). Enrichment factor is used as an index of apoptosis. An
increase in the enrichment factor of 1.0 corresponded ap–
proximately to 8–12% of apoptotic cells as determined in parallel
by Fluorescence-activated cell sorting (FACS) analysis after
staining with FITC-labeled annexin V (Alexis Biochemicals, San
Diego, USA) (data not shown).
Detection of HSP60 and TLR4 activation
For FACS analysis, we incubated cells with specific or control
antibodies for 30 minutes on ice. Antibody binding was revealed
using fluorescein isothiocyanate (FITC)-conjugated secondary
antibodies. Samples were run on a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA).
Soluble HSP60 released in the supernatant was evaluated using
a commercially available kit (Stressgen, Victoria, BC, Canada).
Surface expression of HSP60 was assessed by FACS analysis using
a monoclonal antibody directed against HSP60 (clone KL-1,
Stressgen). HUVEC cells stressed with 0,1% glutaraldehyde for
20 minutes on ice were used as positive control.
TLR signaling leads to translocation of NF-kB. To monitor the
induction of TLR4 signaling in response to ligand stimulation, we
have used the pNifty reporter plasmid (Invivogen, Ruschlikon,
Switzerland), expressing the secreted embryonic alkaline phos-
phatase gene (SEAP) under the control of a NF-kB-inducible
ELAM1 composite promoter. Engineered 293T cells stably
transfected with TLR4 and the co-receptors MD2 and CD14
(Invivogen) were co-transfected with the pNifty plasmids. Cells
were grown to 60–80% confluence in growth medium and then
harvested and resuspended in HEK-Blue Detection medium
(Invivogen). This medium is specifically designed for detection of
NF-kB activation since it turns blue in the presence of phosphatase
activity. 2,5610
4 cells/well were plated in 96 well plates in the
presence of the supernatant. Positive control for TLR4 activation
was LPS (Invivogen). Supernatant was devoided of HSP60 using
an anti-HSP60 monoclonal antibody (Stressgen) bound to
a sepharose column. Cells were incubated for 24 hrs at 37uCi n
5% CO2 and the blue color assessed by a spectrophotometer set at
620 nm. The supernatants used in this set of experiments were
devoided of LPS contaminants using detoxy-gel endotoxin
removing columns (Pierce Biotechnology, Rockford, IL, USA).
Mock-transfected 293T cells were used as negative control.
Gene Array analysis
Cell pellets of endothelial cells cultured as previously described
and obtained after 6 and 12 hours of incubation with affinity
purified antibodies against US28, UL122 and an irrelevant
peptide, were used for gene array experiments. Preparation of
cRNA, hybridization, and scanning of probe arrays were
performed according to the protocols of the manufacturer
(Affymetrix Santa Clara, California, United States) by the
Genopolis Consortium (University of Milano-Bicocca, Italy) using
the Human Genome U133A GeneChip
H (Affymetrix). The
GeneChip
H Human Genome U133A is a single array representing
14,500 well-characterized human genes and including more than
22,000 probe sets and 500,000 distinct oligonucleotide features.
The different gene expression patterns were analyzed using the
Array Assist software version 2.0 (Stratagene, La Jolla, California,
United States) that calculated a robust multi-array average of
background-adjusted, normalized, and log-transformed intensity
values applying the Robust Multi-Array Average algorithm
(RMA). With this software the mean optical background level
for each array was subtracted from the signal intensity for each
probe. Finally, the normalized, background-corrected data were
transformed to the log2 scale. A Signal Log2 Ratio of 1.0 indicates
an increase of the transcript level by two fold change (2 F.C.)
hCMV and Atherosclerosis
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Ratio of zero would indicate no change [9].
In our study, we analyzed the gene expression profiles in
endothelial cells stimulated with antibodies purified against either
the UL122 or the US28 peptide (test samples) or with antibodies
purified against an irrelevant peptide (control samples) for 6 and
12 hours. Genes were selected for final consideration when their
expression (F.C.) was at least 1.5-fold different in the test sample
versus control sample at least at one time point. Experiments were
performed in duplicates. The microarray results have been
reported according to the MIAME guidelines and deposited in
the public repository Array-Express at http://www.ebi.ac.uk/
arrayexpress.
To verify relationships from our gene list and the existing
knowledge in the literature concerning genes and atherosclerosis,
we used the automated literature mining tool, termed MedGene
(hptt://hipseq.med.harvard.edu/MEDGENE/login.jsp), which
summarizes and estimates the relative strength of all human gene
disease relationships in Medline [10].
The software package Pathway Studio (Ariadne Genomics,
Rockville USA) was used to identify functional interrelationships
among the genes identified. These functional relationships were
then graphically represented by the software as a network.
Validation of Gene Array results
Quantitative real-time polymerase chain reaction (Q-PCR) was
carried out as described [9]. Briefly, total RNA has been extracted
from HUVECs with TRIzol reagent (Invitrogen, Carlsbad, CA,
USA), following manufacturer’s instructions. One mg of total RNA
from each sample was treated with amplification grade DNase I
and then used as a template for the reverse transcription reaction,
using random hexamers and SuperScript II Reverse Transcriptase
(Invitrogen). All samples will be reverse transcribed under the
same conditions and from the same reverse transcription master
mix, in order to minimize differences in reverse transcription
efficiency. Triplicate Q-PCR reactions for each sample have been
performed. Control wells containing no template have been used
to exclude the presence of contaminating template molecules and
to identify potential primer-dimer products from the dissociation
curve analysis. Amplification plots have been analyzed using
Opticon Monitor software version 2.02 (MJ Research, Waltham,
MA, USA) and data calculated with Q-Gene software (www.
BioTechniques.com) and expressed as mean normalized expres-
sion (MNE). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) has been used as a normalizing gene according to its
stable expression levels.
Detection of MCP-1 (Amersham Biosciences, Pisacataway, NJ,
USA) and sE-Selectin (R&D Systems, Minneapolis, Minnesota,
USA) in the supernatants were determined by ELISA.
Statistical analysis
Statistical testing was performed using StatsDirect (StatDirect,
Cheshire, UK). Difference in the concentration of soluble
molecules in the supernatants was performed using a parametric
test. P-values less than 0.05 was considered significant.
RESULTS
The IgG antibodies affinity purified against the HSP60 and the
viral peptides obtained from patients with CAD had the same
behaviour of the purified antibodies previously described both in
the recognition of endothelial cell surface molecules and in the
ability to induce endothelial cell apoptosis [6]. To more precisely
analyze the mechanisms by which anti-hCMV-derived proteins
UL122 and US28 antibodies induce apoptosis of HUVECs [6],
a time course experiment was performed by incubating HUVECs
with either anti-UL122 or anti-US28 or anti-irrelevant peptide
antibodies obtained from the 10 patients with CAD. Figure 1,
panels A and B, shows that apoptosis induced by anti-UL122
antibodies occurs at an earlier stage compared to the other anti-
hCMV antibody subset. Moreover internucleosomal DNA
fragmentation induced by anti-UL122 peptide antibodies reached
80% and that induced by anti-US28 reached 72% of the level of
internucleosomal DNA fragmentation seen after exposure of
endothelial cells to 50 mg/L of TNFalpha. This finding is in
accordance with our previous report that the antibodies can
trigger apoptosis in human endothelial cells upon interaction with
different cell-membrane molecules through a mechanism of
molecular mimicry [6]. Antibodies against HSP60 play a pivotal
role in the cytotoxic damage of stressed endothelial cells; since
antibodies against hCMV are able to crossreact with particular
HSP60 epitopes thus amplifying the cell damage by binding
surface HSP60, we evaluated the surface HSP60 expression in
endothelial cells after exposure to anti-UL122 and US28
Figure 1. Anti-hCMV antibodies induce apoptosis of endothelial cells.
Apoptosis induced in HUVECs by antibodies directed against UL122
peptide (A) and against US28 peptide (B); X axis: apoptotic index; Y axis:
time expressed in hours. Data are mean of three independent
experiments. Error bars=SD. Apoptosis induced by antibodies directed
against the irrelevant peptide gave an apoptotic index,1 at all time
points, corresponding to less than 8–12% of apoptotic cells as
determined in parallel by FACS analysis.
doi:10.1371/journal.pone.0000473.g001
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antibodies translocated HSP60 on the cell surface (figure 2, panels
A–C) and released the soluble molecule (sHSP60) in the medium
(figure 3). These data suggest that the two antibody subsets induce
apoptosis through different mechanisms: anti-UL122 antibodies
induce apoptosis through the engagement of the surface molecules
CD151 and connexin 45 (GJA7), whereas the apoptotic damage
triggered by the engagement of CD49f (ITGA6) by anti-US28 can
be further amplified by the antibody interaction with HSP60
expressed on the cell surface.
Since a link between innate immunity and atherosclerosis has
been proposed and several data indicate that signaling through
TLR4 promotes atherosclerosis [11], and since HSP60 has been
proposed as an endogenous ligand for TLR4 [12], we next
evaluated whether HSP60 present in the supernatant of
endothelial cells stimulated with anti-US28 antibodies could
engage TLR4. 293T cells transfected with TLR4 were activated
by the supernatant that induced an activation of TLR4 similar to
the one obtained with 40 ng of LPS (figure 4). Such activation was
not present when the supernatant was deprived of HSP60 and
when supernatant was used with mock-transfected 293T cells.
These data suggest that HSP60 is indeed an endogenously
generated ligand for TLR4.
We next analyzed the gene expression profiles in endothelial
cells treated with antibodies affinity purified against the hCMV-
derived peptides in order to identify clusters of genes involved in
the pathogenesis of vascular damage in atherosclerosis. Anti-US28
peptide antibodies up-regulated 907 transcripts (Table 1 and
Table S1). Clustergrams of modulated genes are shown in figure 5.
Anti-US28 antibodies up-regulated genes encoding for adhesion
molecules, such as E selectin, VCAM-1 and ICAM-1 and genes
encoding for chemokines including CCL2, CCL20, CXCL1,
CXCL2, together with chemokine receptors such as CCR3,
CXCR4.
Genes encoding for molecules involved in the apoptotic process
were induced including eukaryotic translation initiation factor 5
(EIF5A) [13], which induces the expression of proteins essential for
apoptosis of HUVECs, and other apoptosis-related genes such as
caspase-6 (CASP6) and CASP7 and DNA fragmentation factor
(DFFA). Up-regulated transcription factors included transcription
factor 4 (TCF4) and v-ets erythroblastosis virus E26 oncogene
homolog 2 (ETS2), involved in promoting apoptosis [14].
Moreover some ribosomal proteins were highly induced (up to
Figure 2. FACS analysis of the expression of HSP60 at the cell surface membrane. (A) Positive control: HUVECs stressed with glutaraldehyde for
20 minutes; (B) HUVECs treated with anti-UL122 antibodies for 9 hours; (C) HUVECs treated with anti-US 28 antibodies for 9 hours. HUVEC cells were
stained with a monoclonal antibody directed against HSP60. Percentage of positive cells: (A) 44,2%; (B) 1,3%; (C): 6,7%.
doi:10.1371/journal.pone.0000473.g002
Figure 3. Soluble HSP60 in the supernatant of stimulated cells.
Soluble HSP60 in the supernatant (SN) of HUVECs after stimulation with
anti-US28 and anti-UL122 antibodies (Abs) at different time points. X
axis: time expressed in hours. Y axis: soluble HSP60 concentration
expressed in ng/ml.
doi:10.1371/journal.pone.0000473.g003
Figure 4. TLR4 activation by the supernatant of treated cells. TLR4 engagement by the SN of cells treated with the antibodies (Abs) described. Y
axis: levels of TLR4 stimulation expressed as ng/mL of LPS. Data are mean of three independent experiments. Error bars=SD.
doi:10.1371/journal.pone.0000473.g004
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PLoS ONE | www.plosone.org 4 May 2007 | Issue 5 | e473Table 1. Gene expression in HUVEC after 6 and 12 huors of stimulation with anti-US28 IgG antibodies
..................................................................................................................................................
Gene accession Gene description Gene Symbol F.C. 6 h F.C.12 h
Adhesion molecules
NM_000450.1 endothelial adhesion molecule 1 SELE 5,95 1,79
NM_001078.2 vascular cell adhesion molecule 1 VCAM1 3,76 2,06
NM_002203.2 integrin, alpha 2 ITGA2 2,61 2,69
NM_000212.2 integrin, beta 3 ITGB3 1,72 1,72
NM_000201.1 intercellular adhesion molecule 1 (CD54) ICAM1 1,60 1,33
Inflammation
S69738.1 chemokine (C-C motif) ligand 2 CCL2 2,46 1,98
NM_004591.1 chemokine (C-C motif) ligand 20 CCL20 1,63 1,42
NM_001511.1 chemokine (C-X-C motif) ligand 1 CXCL1 3,32 1,63
M57731.1 chemokine (C-X-C motif) ligand 2 CXCL2 4,21 2,72
NM_002090.2 chemokine (C-X-C motif) ligand 3 CXCL3 1,62 1,40
NM_001837.2 chemokine (C-C motif) receptor 3 CCR3 1,49 1,77
AJ224869 chemokine (C-X-C motif) receptor 4 CXCR4 2,24 1,99
NM_017801.2 chemokine-like factor super family 6 CKLFSF6 2,07 1,69
NM_003326.2 tumor necrosis factor (ligand) superfamily, member 4 TNFSF4 1,96 1,36
NM_002184.2 interleukin 6 signal transducer IL6ST 3,61 4,36
NM_002185.2 interleukin 7 receptor IL7R 2,04 2,01
Immune responce
NM_000593.3 transporter 1, ATP-binding cassette, sub-family B TAP1 1,98 1,85
NM_005348.2 heat shock 90kDa protein 1, alpha HSPCA 2,11 1,84
NM_006260.2 DnaJ (Hsp40) homolog, subfamily C, member 3 DNAJC3 1,78 1,65
Transcription
NM_005239.4 v-ets erythroblastosis virus E26 oncogene homolog 2 ETS2 3,21 2,34
NM_003199.1 transcription factor 4 TCF4 3,12 3,42
NM_021964.1 zinc finger protein 148 ZNF148 3,53 2,92
BC003566.1 zinc finger protein 24 ZNF24 3,44 2,76
BC003070.2 GATA binding protein 3 GATA3 1,91 1,50
NM_007348.2 activating transcription factor 6 ATF6 2,79 2,69
U97103.1 alpha thalassemia/mental retardation syndrome X-linked ATRX 4,68 4,41
NM_013448.2 bromodomain adjacent to zinc finger domain, 1A BAZ1A 3,98 4,62
NM_013354.5 CCR4-NOT transcription complex, subunit 7 CNOT7 1,71 1,60
NM_004459.5 fetal Alzheimer antigen FALZ 2,97 3,00
AF548661 general transcription factor IIH, polypeptide 3, 34kDa GTF2H3 3,33 3,68
NM_003489.2 nuclear receptor interacting protein 1 NRIP1 11,86 8,12
NM_004774.2 PPAR binding protein PPARBP 2,88 2,67
Inhibition of cell growth and apoptosis
NM_001970.3 eukaryotic translation initiation factor 5A EIF5A 22,93 17,78
BC000076.2 cyclin D1 (PRAD1: parathyroid adenomatosis 1) CCND1 2,03 2,04
NM_003810.2 tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 2,03 2,53
U20537.1 caspase 6, apoptosis-related cysteine protease CASP6 2,65 2,35
NM_001227.3 caspase 7, apoptosis-related cysteine protease CASP7 1,61 1,31
NM_005256.2 growth arrest-specific 2 GAS2 1,84 1,19
BC001152.1 growth arrest-specific 7 GAS7 1,78 1,95
NM_004401.2 DNA fragmentation factor, 45kDa, alpha polypeptide DFFA 1,23 1,66
NM_020529.1 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha NFKBIA 2,40 1,75
AF091555.1 C-terminal binding protein 1 CTBP1 6,48 5,10
NM_021111.1 reversion-inducing-cysteine-rich protein with kazal motifs RECK 1,74 1,74
NM_016272.3 transducer of ERBB2, 2 TOB2 1,92 1,99
BC006325.2 G-2 and S-phase expressed 1 GTSE1 1,92 1,92
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PLoS ONE | www.plosone.org 5 May 2007 | Issue 5 | e473119,98 fold change in expression for RPS11) as already observed
in HUVECs treated with asymmetrical dimethylarginine (ADMA),
an endogenous inhibitor of nitric oxide synthase considered a risk
factor for cardiovascular disease [15]. Interestingly ribosomal
protein S19 is over-expressed during apoptotic cell death [16].
Genes involved in the mitogen-activated protein kinase (MAPK)
signal pathway, which plays a pitoval role in transmitting
transmembrane signals required for cell proliferation and
Gene accession Gene description Gene Symbol F.C. 6 h F.C.12 h
Collagens and extracellular matrix
NM_005713.1 collagen, type IV, alpha 3 binding protein COL4A3BP 1,76 1,87
NM_006665.2 heparanase HPSE 1,74 1,33
NM_021809.4 TGFB-induced factor 2 (TALE family homeobox) TGIF2 1,69 1,13
NM_003243.2 transforming growth factor, beta receptor III (betaglycan) TGFBR3 1,55 1,61
Metabolism
NM_014508.2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C APOBEC3C 1,88 2,00
BC015818.1 lectin, galactoside-binding, soluble, 8 (galectin 8) LGALS8 2,78 1,38
NM_002858.2 ATP-binding cassette, sub-family D (ALD), member 3 ABCD3 1,86 1,50
NM_017526.2 leptin receptor LEPR 1,74 1,98
AF285167.1 ATP-binding cassette, sub-family A,1 ABCA1 1,52 1,11
NM_005506.2 scavenger receptor class B, member 2 SCARB2 1,42 1,88
Growth factors
NM_002632.4 placental growth factor PGF 3,34 3,02
Receptors
NM_000875.2 insulin-like growth factor 1 receptor IGF1R 4,41 3,99
AW157070 epidermal growth factor receptor precursor EGFR 3,11 2,57
M34641 fibroblast growth factor receptor 1 FGFR1 2,47 2,61
NM_000565.2 interleukin 6 receptor IL6R 1,55 1,31
NM_000808.2 gamma-aminobutyric acid (GABA) A receptor, alpha 3 GABRA3 1,43 1,58
Enzymes
NM_003358.1 UDP-glucose ceramide glucosyltransferase UGCG 3,50 2,73
AF065214.1 phospholipase A2, group IVC (cytosolic, calcium-independent) PLA2G4C 3,36 3,64
NM_001394.5 dual specificity phosphatase 4 DUSP4 3,06 2,69
NM_024906.1 stearoyl-CoA desaturase 4 SCD4 2,45 1,57
NM_006888.2 calmodulin 1 CALM1 5,48 5,56
M61906.1 phosphoinositide-3-kinase, regulatory subunit (p85 alpha) PIK3R1 2,25 2,31
L18964.1 protein kinase C, iota PRKCI 2,21 2,60
BC005365.1 mitogen-activated protein kinase kinase 7 MAP2K7 2 2,45
Solute carriers
NM_000112.2 solute carrier family 26 (sulfate transporter), member 2 SLC26A2 5,70 4,53
NM_004731.3 solute carrier family 16 (monocarboxylic acid transporters), member 7 SLC16A7 2,92 2,11
Small G proteins
AI189609 RAB2, member RAS oncogene family RAB2 2,64 2,93
NM_022157.2 Ras-related GTP binding C RRAGC 2,19 1,25
Miscellaneuos
NM_001015.3 ribosomal protein S11 RPS11 119,98 40,70
BC000603.2 ribosomal protein L38 RPL38 31,39 15,66
BC000023.2 ribosomal protein S19 RPS19 3,08 3,08
M25077 Sjogren syndrome antigen A2 (60kDa, ribonucleoprotein autoantigen SS-A/Ro) SSA2 2,38 2,12
AF055585.1 slit 2 SLIT2 2,16 1,66
NM_014399.3 transmembrane 4 superfamily member 13 TM4SF13 1,56 1,60
AF065241.1 thioredoxin (stress-induced) TXN 2,43 2,04
NM_006287.3 tissue factor inhibitor protein TFPI 6,64 7,77
NM_033360.2 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog KRAS2 8,92 8,48
doi:10.1371/journal.pone.0000473.t001
Table 1. cont.
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e473apoptosis, were up-regulated by anti-US28 antibodies, including
MAP2K7 (or MKK7), one of the major SAPK/JNK activating
kinases [17], calmodulin 1 (CALM1) [18] and phosphatidylinositol
3-kinase regulatory 1 (PIK3R1). The activation of the MAPK
pathway is responsible of the activation of other regulatory
proteins, including the cytosolic enzyme phospholipase A2
(PLA2G4C), upregulated by anti-US28 antibodies, known to be
induced in HUVECs in response to hypoxia, with consequent
release of arachidonic acid [19].
Induction of growth factors is a common feature of endothelial
cell activation; interestingly placental growth factor (PGF), known
to promote atherosclerotic intimal thickening and macrophage
accumulation [20], was induced by anti-US28 peptide antibodies.
Moreover epidermal growth factor receptor (EGFR) and fibroblast
growth factor receptor 1 (FGFR1), both induced by anti-US28
antibodies, are expressed in atherosclerotic plaques [21,22]. Finally,
several other genes were up-regulated including genes involved in
lipid metabolism such as leptin receptor (LEPR), ATP-binding
cassette (ABCA1) and peroxisome proliferator-activated receptor
binding protein (PPARBP), and in extracellular matrix metabolism:
collagen type IV alpha 3 binding protein (COL4A3BP), heparanase
(HPSE), TGF beta-induced factor 2 (TGIF2).
Among the 1379 transcripts down-regulated by anti-US28
antibodies (Table S2) there were endothelial nitric oxide synthase
(eNOS) and LDL receptor. The gene encoding for the anti-
apoptotic molecule programmed cell death 4 protein (PDCD4)
was repressed, accordingly to the observation that endothelial cells
undergo apoptosis. Interestingly we could observe a down-
regulation of HSP70, reported to exert a protective role against
the development of atherosclerosis [23].
Anti-UL122 peptide antibodies up-regulated 186 transcripts
including genes encoding for adhesion molecules, chemokines,
transcription factors and molecules involved in apoptosis (Table 2
and Table S3). The highest increase in expression was observed
among genes encoding for adhesion molecules: selectin E, VCAM-
1 and ICAM-1. Another cluster of up-regulated genes was
represented by genes encoding for inflammatory molecules
including chemokines; CCL2, was highly increased, with a peak
of 19-fold increase in expression at 6 hrs of stimulation. Others
chemokine genes were highly induced, including CCL20, CXCL2,
CXCL3 and CX3CL1. Genes encoding for extracellular matrix
and matrix remodeling proteins [24] were also found up-regulated:
matrix metalloproteinase-10 (MMP-10), laminin, nidogen, colla-
gen type IV and cathepsin S. Several genes encoding for molecules
involved in apoptosis such as CASP7, tumor necrosis factor alpha-
induced protein 1 (TNFAIP1), and TNFAIP2 were upregulated.
Similarly to what observed with anti-US28 peptide antibodies,
anti-UL122 antibodies induced up-regulation of transcription
factors, in particular genes involved in NF-kB activation pathway
such as TANK and RELB, which have been implicated in
atherosclerosis [25]. Moreover genes encoding for a variety of
proteins that have been associated with atherosclerosis were up-
regulated including phospholipase A2 (PLA2G4C), prostaglandin
synthase 2 (PTGS2) also known as cyclooxygenase-2, thrombin
receptor like-1 and the gene encoding for superoxide dismutase 2
(SOD2).
A total number of 140 transcripts were down-regulated by anti-
UL122 antibodies (Table S4). Some genes are involved in lipid
metabolism: 24-dehydrocholesterol reductase (DHCR24), squa-
lene epoxidase (SQLE), LDL receptor and low density lipoprotein
receptor-related protein 8 (LRP8). The decreased expression of the
gene encoding for eNOS has already been reported in endothelial
cells isolated from patients with vascular damage indicating an
intrinsic defect in the mechanism of nitric oxide production [26].
Figure 5. Gene array analysis of HUVECs stimulated with anti-hCMV
antibodies. Clustergrams of genes modulated by incubation of
endothelial cells with antibodies against the US28 peptide or the
UL122 peptide. Colours indicate the fold change.
doi:10.1371/journal.pone.0000473.g005
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PLoS ONE | www.plosone.org 7 May 2007 | Issue 5 | e473Table 2. Gene expression in HUVEC after 6 and 12 hours of stimulation with anti-UL122 IgG antibodies
..................................................................................................................................................
Gene accession Gene description Gene Symbol F.C. 6 h F.C.12 h
Adhesion molecules
NM_000450.1 selectin E (endothelial adhesion molecule 1) SELE 31,15 15
NM_001078.2 vascular cell adhesion molecule 1 VCAM1 18,8 6,1
NM_000201.1 intercellular adhesion molecule 1 (CD54) ICAM-1 12,7 7,2
NM_002210.2 integrin, alpha V ITGAV 1,54 1,32
Inflammation
S69738.1 chemokine (C-C motif) ligand 2 CCL2 19 16
NM_004591.1 chemokine (C-C motif) ligand 20 CCL20 7,6 4,7
NM_001511.1 chemokine (C-X-C motif) ligand 1 CXCL1 6,2 4,5
M57731.1 chemokine (C-X-C motif) ligand 2 CXCL2 9,5 6,8
NM_002090.2 chemokine (C-X-C motif) ligand 3 CXCL3 10 6
NM_002994.3 chemokine (C-X-C motif) ligand 5 CXCL5 2 2
NM_002993.2 chemokine (C-X-C motif) ligand 6 CXCL6 2 1,8
NM_000584.2 interleukin 8 IL8 2,8 2,3
NM_005409.3 chemokine (C-X-C motif) ligand 11 CXCL11 5,5 6
NM_002996.3 chemokine (C-X3-C motif) ligand 1 CX3CL1 3,11 2,9
NM_002341.1 lymphotoxin beta (TNF superfamily, member 3) LTB 1,67 1,6
NM_005658.3 TNF receptor-associated factor 1 (TRAF1) TRAF1 1,6 1,37
NM_003300.2 TNF receptor-associated factor 3 (TRAF3) TRAF 3 1,6 1,45
NM_000395.1 colony stimulating factor 2 receptor, beta CSF2RB 1,52 1,2
AJ224869 chemokine (C-X-C motif) receptor 4 CXCR4 1,83 2,17
NM_004221.4 natural killer cell transcript 4 (interleukin 32) NK4 1,6 4,3
NM_003855.2 interleukin 18 receptor 1 IL18R 2,02 1,3
Immune response
X56841.1 major histocompatibility complex, class I, E HLA-E 1,2 1,5
NM_000593.5 transporter 1, ATP-binding cassette, sub-family B TAP 1 1,8 2,14
NM_006260.2 DnaJ (Hsp40) homolog, subfamily C, member 3 DNAJC3 1,19 1,63
Transcription
NM_003440.2 zinc finger protein 140 ZNF140 1,6 1,3
NM_002448.2 msh homeo box homolog 1 MSX1 1,8 1,7
NM_006509.2 v-rel reticuloendotheliosis viral oncogene homolog B RELB 2 2
NM_003199.1 transcription factor 4 TCF4 1,6 1,5
NM_030751.2 transcription factor 8 TCF 8 1,4 1,8
NM_004556.2 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon NFKBIE 2 1,8
NM_000222.1 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene KIT 2,3 2,2
U59863.1 TRAF family member associated NFKB activator TANK 1,6 1,4
NM_005239.4 v-ets erythroblastosis virus E26 oncogene homolog 2 ETS2 1,26 1,53
NM_003489.2 nuclear receptor interacting protein 1 NRIP1 1,67 1,60
Inhibition of cell growth and apoptosis
NM_006291.2 tumor necrosis factor, alpha-induced protein 2 TNFAIP2 2,37 1,57
NM_021137.3 tumor necrosis factor, alpha-induced protein 1 (endothelial) TNFAIP1 1,7 1,44
NM_001227.3 caspase 7, apoptosis-related cysteine protease CAS P7 1,68 1,35
NM_000546.2 tumor protein p53 TP53 1,2 1,7
NM_006290.2 tumor necrosis factor, alpha-induced protein 3 TNFAIP3 2,7 2,44
NM_003810.2 tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 2,3 3,39
NM_020529.1 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor NKFBIA 2,7 2,3
Collagens and extra-cellular matrix
NM_007361.2 nidogen 2 (osteonidogen) NID2 1,8 2,9
NM_001846.1 collagen, type IV, alpha 2 COL4A2 1,5 2,4
NM_001845.3 collagen, type IV, alpha 1 COL4A1 1,75 1,85
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PLoS ONE | www.plosone.org 8 May 2007 | Issue 5 | e473The gene array results were validated by real-time PCR of some
of the genes up-regulated by both anti-US28 and UL122
antibodies (figure 6 A, B). These findings were paralleled by
increased secretion of the corresponding molecules in the
supernatant of stimulated cells (figure 7 A, B).
Using MedGene, the automated literature mining tool which
summarizes and estimates the relative strength of all human gene
disease relationships in Medline, the transcripts induced after
stimulation with anti US28 antibodies were sorted into 3 classes,
according to their relationship with the disease Atherosclerosis: 95
Gene accession Gene description Gene Symbol F.C. 6 h F.C.12 h
NM_002999.2 syndecan 4 SDC4 1,5 1,36
NM_004079.3 cathepsin S CTSS 1,2 1,58
NM_002425.1 matrix metalloproteinase 10 MMP10 1,7 2,3
NM_005562.1 laminin,gamma 2 LAMC2 1,5 2,3
Metabolism
NM_014349.2 apolipoprotein L, 3 APOL3 2,4 1,7
AF065214.1 phospholipase A2 PLA2 G4C 5,1 10,8
NM_004915.3 ATP-binding cassette, sub-family G (WHITE), member 1 ABCG1 3 2,8
Miscellaneous
L07555.1 CD69 antigen CD 69 6 3,7
NM_004428.2 ephrin-A1 EFNA1 2,1 1,8
NM_000963.1 prostaglandin-endoperoxide synthase 2 (COX-2) PTGS2 1,9 1,3
NM_005242.3 Thrombin receptor like 1 F2RL1 1,72 1,63
NM_003277.2 Claudin 5 CLDN5 1,17 1,7
AY267901.1 superoxide dismutase 2, mitochondrial SOD 2 5,5 4,6
NM_021804.1 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 ACE2 1,2 1,5
NM_006398.2 ubiquitin D UBD 2,7 3,8
NM_002053.1 guanylate binding protein 1, interferon-inducible, 67kDa GBP1 1,8 1,7
doi:10.1371/journal.pone.0000473.t002
Table 2. cont.
..................................................................................................................................................
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Figure 6. Validation of gene array by Q-PCR. (A) Genes selected for validation by Q-PCR in endothelial cells treated with anti-US28 peptide
antibodies. CCL2, E-selectin, VCAM-1 and CXCL2 transcripts were increased by 2,46-, 5,95-, 3,76-, and 4,21-fold, respectively, compared with control
endothelial cells. (B) Genes selected for validation by Q-PCR in endothelial cells treated with anti-UL122 antibodies. CCL2, E-selectin, VCAM-1 and
ICAM-1 transcripts were increased 19-, 31,15-, 18,8-, and 12,7-fold compared to control endothelial cells. The level of transcript expression is reported
on the vertical axis. GAPDH was selected as endogenous gene.
doi:10.1371/journal.pone.0000473.g006
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PLoS ONE | www.plosone.org 9 May 2007 | Issue 5 | e473genes were directly associated to atherosclerosis, 348 were
associated through others genes and 263 genes were new for this
disease. Similarly, among the genes up-regulated by anti-UL122
antibodies, 40 genes resulted directly linked to atherosclerosis, 88
genes have been indirectly associated with the disease, and only 33
genes non associated to the atherosclerosis. Considering the down-
regulated genes, 329 were not related to the disease after US28
antibody stimulation and 33 resulted not previously associated to
the disease after UL122 antibody stimulation. A total of 25 genes
were up-regulated by both anti-hCMV antibodies, while 26 genes
were simultaneously down regulated by both anti-hCMV
antibodies (Table S5 and Table S6). Interestingly all of these
genes are classified as ‘‘directly related to atherosclerosis’’ when
analyzed with MedGene.
We next wanted to identify the biological processes influenced
by the engagement of CD49f and HSP60, connexin 45 and
Figure 7. Soluble mediators released in cell culture supernatants. (A, B) Quantification of CCL2 released in the supernatant (SN) of HUVECs
stimulated with antibodies (Abs) against the irrelevant peptide and with anti-UL122 and anti-US28 affinity purified antibodies. (C, D) Quantification of
soluble E-selectin in the SN of HUVECs stimulated with abs against the irrelevant peptide and with anti–UL122 and anti-US28 affinity purified
antibodies. Results are expressed in pg/mL and ng/mL, respectively. Results are expressed as mean of three independent experiments.
doi:10.1371/journal.pone.0000473.g007
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PLoS ONE | www.plosone.org 10 May 2007 | Issue 5 | e473CD151 in HUVECs treated with either anti-US28 or anti-UL122
antibodies by using a pathway analysis software (Pathway Studio).
To answer this question we generated connection pathways linking
either CD151 and Connexin 45 or CD49f and HSP60 with the
sets of modulated genes. The graphic outputs obtained showed
that the different receptors use different pathways which ultimately
lead to the same biological processes, including immune response,
inflammation and apoptosis (Figure S1).
DISCUSSION
We had previously reported that antibodies isolated from patients
with atherosclerosis and directed against the hCMV-derived
proteins UL122 and US28 are able to induce endothelial cell
apoptosis following the engagement of cell surface molecules [6].
The apoptotic process was more evident when HUVEC cells were
exposed to anti-UL122 antibodies and here we show that these
antibodies induce apoptosis earlier than anti-US28 antibodies do.
Anti-US28 antibodies induce membrane translocation and release
in the supernatant of HSP60. Abnormal surface expression of
HSP60 sensitizes endothelial cells to apoptosis and cross-
recognition of HSP60 on stressed endothelial cells by such
antibodies may amplify the process. HSP60 is released in the
supernatant and is able to trigger signaling through TLR4,
suggesting a possible a link between the atherosclerotic process and
defence against both foreign pathogens and endogenously
generated inflammatory ligands [11]. Indeed TLR4 may play
a pivotal role in the early stages of atherosclerosis since it is
upregulated on endothelial cell by low shear stress and oxidized
lipoproteins. On the other hand TLR4 initiates an immune
response after recognition of pathogen-associated molecular
patterns inducing upregulation of proinflammatory cytokines.
HSP60, released upon stress signals, acts as an endogenous ligand
for TLR4, thus amplifying TLR4 activity and suggesting a HSP60-
related autocrine process [27]. Moreover it has been reported that
ligation of TLR strongly inhibits cholesterol efflux from macro-
phages [28]. Therefore TLR4 may bridge oxidized lipoproteins,
infection, inflammation and low shear stress in the pathogenesis of
the disease [29].
To investigate the gene modulation induced by anti-hCMV
antibodies, we used a gene array approach, which allows the
simultaneous detection of thousands of genes in a given sample. By
this approach we found that the purified anti-hCMV antibodies
modulate a vast array of genes encoding for molecules which play
a pivotal role in endothelial cells activation and damage.
Interestingly the genes associated to atherosclerosis VCAM1,
SELE, ICAM1, CCL2, CCL20, CXCL2, TAP1, NFKBIA, TCF4
and ABCG1 are upregulated in cells treated with both UL122 and
US28. The up-regulation of genes encoding for the adhesion
molecules ICAM-1, VCAM-1, E-selectin is present also when
endothelial cells are stimulated by proinflammatory cytokines such
as tumor necrosis factor alpha [30]. These adhesion molecules are
markers of endothelial dysfunction and damage and have been
found elevated in the sera of patients affected by atherosclerosis
[31]. Reflecting the inflammatory status of the atherosclerotic
process [32], different chemokine-encoding genes have been
reported to be activated in endothelial cells [33]. Also in our
experimental model, some chemokine-endoding genes were up-
regulated, in particular the gene encoding for CCL2 presented the
highest fold change, mainly in the cells treated with anti-UL122
antibodies. This result was confirmed by the high increase in
CCL2 transcripts by Q-PCR and by the detection of increased
levels of the molecule in the cell culture supernatants.
Genes involved in the extracellular matrix metabolism were also
up-regulated reflecting the extracellular matrix rearrangement
within the vessel walls during the atherosclerotic process [24]. The
gene expression profile in our cells resulted in the up-regulation of
genes encoding for several transcription factors and proteins
involved in the intracellular signaling. In particular in cells
stimulated with anti-US28 antibodies the genes encoding for
ETS2 and calmodulin 1 were highly induced. In this context it has
to be mentioned that different stress factors, (i.e. mechanical force
and thrombin) may initiate intracellular signaling relevant to
vascular damage [34]. Moreover, TANK and RELB induced in
anti-UL122 treated cells, as well as MAPK induced by anti-US28
antibodies, are involved in the NF-kB activation, known to play
a pivotal role in the regulation of several genes related to
atherogenesis [25]. Finally the diminished expression of endothe-
lial eNOS is an early event in endothelial cell damage and
a suppressed eNOS activity has been recently reported in hCMV
infected endothelial cells [35].
It is noteworthy that all of the genes modulated by the two
subsets of anti-hCMV antibodies encode molecules that have been
already associated with atherosclerosis [36], supporting the
possible role of hCMV in inducing endothelial cell damage that
plays a pivotal role in the atherosclerotic process.
Taken together these data indicate that the anti-UL122 and -
US28 antibodies induce endothelial cell damage through the
activation of genes encoding for adhesion molecules, chemokines,
for molecules involved in immune response, inflammation and
extracellular matrix deposition. Moreover anti-US28 antibodies
ampliphy their effect on endothelial cells through the traslocation
of HSP60 on cell surface.
Since these subset of anti-hCMV antibodies have been detected
in the majority of patients with atherosclerosis [6], our results give
further support to the role played by hCMV in the pathogenesis of
the disease.
SUPPORTING INFORMATION
Figure S1 Functional pathway analysis of genes influenced by
the engagement of CD151 and connexin 45 (A) and CD49f and
HSP60 (B). The Pathway Studio software was used to identify
connection pathways linking CD151 and connexin 45 or CD49f
and HSP60 with the sets of modulates genes. Genes are
represented as yellow ovals connected by arrows, major biologic
processes related to these genes are represented as orange
rectangles.
Found at: doi:10.1371/journal.pone.0000473.s001 (0.29 MB TIF)
Table S1 Genes up-regulated by anti-US28 antibodies.
Found at: doi:10.1371/journal.pone.0000473.s002 (0.17 MB
XLS)
Table S2 Genes down-regulated by anti-US28 antibodies.
Found at: doi:10.1371/journal.pone.0000473.s003 (0.26 MB
XLS)
Table S3 Genes up-regulated by anti-UL122 antibodies.
Found at: doi:10.1371/journal.pone.0000473.s004 (0.04 MB
XLS)
Table S4 Genes down-regulated by anti-UL122 antibodies.
Found at: doi:10.1371/journal.pone.0000473.s005 (0.03 MB
XLS)
Table S5 Genes up-regulated by both anti-UL28 and anti-
US122 IgG antibodies.
Found at: doi:10.1371/journal.pone.0000473.s006 (0.02 MB
XLS)
Table S6 Genes down-regulated by both anti-US28 and anti-
UL122 antibodies.
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XLS)
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